MoonLake Immunotherapeutics MLTX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's change in accrued liabilities?
- MoonLake Immunotherapeutics (MLTX) reported change in accrued liabilities of $7.12M in Q1 2026.
- How has MoonLake Immunotherapeutics's change in accrued liabilities changed year-over-year?
- MoonLake Immunotherapeutics's change in accrued liabilities increased by 557.8% year-over-year, from -$1.56M to $7.12M.
- What is the long-term trend for MoonLake Immunotherapeutics's change in accrued liabilities?
- Over 2 years (2021 to 2024), MoonLake Immunotherapeutics's change in accrued liabilities has grown at a -16.1% compound annual growth rate (CAGR), from $7.34M to $5.17M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.